Clinical TrialJun 3, 2026, 08:02 AM
Spyre Therapeutics Completes SKYWAY Trial Enrollment; Q3/Q4 2026 Readouts On Track
AI Summary
Spyre Therapeutics announced the completion of enrollment for all sub-studies in its SKYWAY basket trial of SPY072 (anti-TL1A) in rheumatic diseases. The company reiterated its expected Q3 2026 readout for rheumatoid arthritis (RA) and Q4 2026 readouts for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). This progress keeps Spyre on track for five of its six planned Phase 2 readouts in 2026 across the SKYWAY and SKYLINE trials. Additionally, preclinical data supporting SPY072 in rheumatic diseases was presented at the 2026 European Congress of Rheumatology (EULAR).
Key Highlights
- Enrollment completed for all sub-studies in SKYWAY basket trial of SPY072 (anti-TL1A) in rheumatic diseases.
- Expected Q3 2026 readout for rheumatoid arthritis (RA) sub-study.
- Expected Q4 2026 readouts for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies.
- On track for five of six planned Phase 2 readouts in 2026 across SKYWAY and SKYLINE trials.
- Enrollment across all SKYWAY sub-studies completed in less than nine months.
- Preclinical data for SPY072 presented at 2026 European Congress of Rheumatology (EULAR) on June 4.
- SPY072 targets over three million U.S. patients with RA, PsA, and axSpA.
Price Impact
More from SYRE